References
- Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review 1975–2006, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2006/
- Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–988.
- D’Antonio J. Chronic myelogenous leukemia. Clin J Oncol Nurs 2005;9:535–538.
- Faderl S, Talpaz M, Estrov Z. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164–172.
- Kalidas M, Kantarijan HM, Talpaz M. Chronic myelogenous leukemia. J Am Med Assoc 2001;286:895–898.
- Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005;25:325–334.
- Dalziel K, Round A, Stein K, et al. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004;8:iii, 1–120.
- Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
- Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
- Etienne G, Nicolini NE, Dulucq S, et al. Achieving a complete molecular remission under imatinib therapy is associated with a better outcome in chronic phase chronic myeloid leukaemia patients on imatinib frontline therapy. Blood 2012;120(Suppl. 1): Abstract 3754.
- Kielhorn A, Graf von der Schulenburg JM. The health economics handbook. 2nd ed. Chester, UK: Adis International; 2000.
- Morris S, Devlin N, Parkin D. Economic analysis in health care. London: Wiley & Sons; 2007.
- Guest JF, Naik N, Sladkevicius E, et al. Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma 2012; 53:928–933.
- Kantarjian HM, O’Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003;97:1033–1041.
- Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood 2010;116:3758–3765.
- Hammerschmidt T, Zeitler H-P, Gulich M, et al. A comparison of different strategies to collect standard gamble utilities. Med Decision Making 2004;24:493–503.
- Trask PC, Cella D, Powell C, et al. Health-related quality of life in chronic myeloid leukemia. Leuk Res 2013;37:9–13.
- Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554–4560.
- Efficace F, Breccia M, Saussele S, et al. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?. GIMEMA and EORTC Quality of Life Group. Ann Hematol 2012;91: 1371–1381.
- Stalmeier PF, Lamers LM, Busschbach JJ, Krabbe PF. On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 2007;45:835–841.